• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Jordan Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Jordan Pharmaceuticals and Healthcare Report Q1 2013

  • Published: January 2013
  • Region: Jordan
  • 112 pages
  • Business Monitor International

FEATURED COMPANIES

  • Company Profiles
  • Dar al-Dawa
  • GlaxoSmithKline
  • Hikma Pharmaceuticals
  • Local Companies
  • Merck & Co
  • MORE

BMI View:

We expect that Jordan will continue to provide modest opportunities to research-based pharmaceutical manufacturers. In line with the authorities' efforts to expand healthcare insurance coverage, we envisage measures aiming to promote the use of cheaper generic medicines, in tandem with price-reduction strategies. Nevertheless, the expansion of government provision and the higher uptake of generic medicines will conspire to keep longer term growth steady, boosted by upward volume changes,
with the patented drug market to continue to be supported by rising numbers of medical tourists.

Headline Expenditure Projections:

- Pharmaceuticals: JOD463mn (US$653mn) in 2011 to JOD501mn (US$707mn) in 2012; +8.1
%in local currency terms and +8.1% in US dollar terms. Forecast unchanged from Q412.

- Healthcare: JOD1.73bn (US$2.45bn) in 2011 to JOD1.87bn (US$2.65bn) in 2012; +8.0% in local currency terms and +8.1% in US dollar terms. Forecast unchanged from Q412.

- Medical devices: JOD112mn (US$158mn) in 2011 to JOD121mn (US$171mn) in 2012; +8.3
%in local currency terms and +8.4% in US dollar terms. Forecast unchanged from Q412.

Risk/Reward READ MORE >

Executive Summary 6

SWOT Analysis 8

Jordan Pharmaceuticals And Healthcare Industry SWOT 8

Jordan Political SWOT 9

Jordan Economic SWOT 10

Jordan Business Environment SWOT 10

Pharmaceutical Risk/Reward Ratings 11
Table: Middle East And Africa Pharmaceutical Risk/Reward Ratings, Q113 11

Rewards 13

Risks 13

Jordan - Market Summary 15

Regulatory Regime 16

Regulatory Developments 17

Intellectual Property Regime 18

IP Concerns 19

Counterfeit Pharmaceuticals 20

Pricing And Reimbursement Regime 21

Pricing And Reimbursement Developments 22

Public Sector Procurement Of Medicines 23

International Collaboration 23

Industry Trends And Developments 25

Epidemiology 25
Table: Primary Health Centre Visits by Condition, 2004-2010 26

Non-Communicable Diseases 26
Table: Diabetes Care Costs In 10 Middle Eastern Countries With Highest Prevalence 28

Communicable Diseases 28
Table: HIV/AIDS Patients, 1986-2010 29
Table: Notifiable Communicable Diseases & Conditions, 2002-2010 29

Healthcare Sector 30

Healthcare Provision 32
Table: MoH Health Centres, 2004-2010 32
Table: Physicians by Sector, 2005-2010 33

Secondary Care 33
Table: Hospitals by Sector, 2001-2010 34

Recent Healthcare Sector Developments 35

Healthcare Funding 36
Table: MoH Budget, 1995-2010 (JOD '000s) 37

Healthcare Insurance 37

Medical Tourism 39

Research And Development Sector 43

Biotechnology 44

Clinical Trials 45

Medical Devices 46

Industry Forecast Scenario 48

Overall Market Forecast 48
Table: Pharmaceutical Sales, 2008-2016 49

Healthcare Market Forecast 50
Table: Overall Healthcare Expenditure, 2008-2016 51
Table: Government Healthcare Expenditure, 2008-2016 52
Table: Private Healthcare Expenditure, 2008-2016 52

Key Growth Factors - Macroeconomic 53
Table: Jordan - Economic Activity 58

Prescription Drug Market Forecast 59
Table: Prescription Drug Sales, 2008-2016 60

Patented Drug Market Forecast 61
Table: Patented Drug Sales, 2008-2016 62

Generic Drug Market Forecast 63
Table: Generic Drug Sales, 2008-2016 64

OTC Medicine Market Forecast 65
Table: OTC Medicine Sales, 2008-2016 66

Pharmaceutical Trade Forecast 67
Table: Pharmaceutical Trade, 2008-2016 70

Medical Device Market Forecast 71
Table: Medical Device Sales, 2008-2016 72

Other Healthcare Data Forecasts 73

Key Risks To BMI's Forecasts 74

Competitive Landscape 75

Pharmaceutical Industry 75

Domestic Pharmaceuticals Sector 76

Foreign Companies 76

Pharmaceutical Wholesale Sector 77

Retail Pharmacy Sector 78
Table: Pharmacists by Sector, 2010 79

Company Profiles 80

Local Companies 80

Pharma International Company 80

Arab Pharmaceutical Manufacturing Company (Hikma) 82

Dar al-Dawa 84

Hikma Pharmaceuticals 87

Jordanian Pharmaceutical Manufacturing Company (JPM) 92

United Pharmaceutical Manufacturers 94

Multinational Companies 96

Pfizer 96

GlaxoSmithKline 97

Novartis 99

Sanofi 00

Merck & Co 01

Demographic Data 102
Table: Population By Age Group, 1990-2020 ('000) 03
Table: Population By Age Group, 1990-2020 (% of total) 04
Table: Key Population Ratios, 1990-2020 05
Table: Rural/Urban Population Split, 1990-2020 05

Glossary 106

BMI Methodology 108

How We Generate Our Pharmaceutical Industry Forecasts 08

Pharmaceutical Risk/Reward Ratings Methodology 09

Ratings Overview 09
Table: Pharmaceutical Risk/Reward Indicators 10

Weighting 11
Table: Weighting Of Components 11

Sources 11

Company Profiles
Local Companies
Pharma International Company
Arab Pharmaceutical Manufacturing Company (Hikma)
Dar al-Dawa
Hikma Pharmaceuticals
Jordanian Pharmaceutical Manufacturing Company (JPM)
United Pharmaceutical Manufacturers
Multinational Companies
Pfizer
GlaxoSmithKline
Novartis
Sanofi
Merck & Co

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos